Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.
By H. von der Maase, L. Sengeløv, James T. Roberts, S. Ricci, L. Dogliotti, T. Oliver, M. Moore, A. Zimmermann, M. Arning. Journal of Clinical Oncology, 2006
936 citations recorded by the source corpus.
Subfields: Epidemiology, Pulmonary and Respiratory Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/c090738af5d51f55879049ee896584ca3e6c4d2d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pulmonary and Respiratory Medicine
In Surgery
Citations in the corpus
- International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. (2011, neutral): “Table 2 shows that neither treatment was risk free, but chemotherapy-related mortality was low (1%) and less than half that reported for methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) in a subsequent international trial of MVAC versus gemcitabine plus cisplatin.(3)”
- Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. (2011, neutral): “8% of patients with visceral metastases [76].”
- The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge (2015, background): “Current treatments for muscle-invasive bladder carcinoma are still limited to cisplatin-based combination chemotherapy, radiotherapy, or surgery, without any second-line treatment, or any defined molecularly targeted factors [69].”
- Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. (2012, background): “Moreover, patients receiving cisplatin have a small but realistic chance of long-term survival.(34,35) At a median follow-up of 4.”
- Comprehensive Molecular Characterization of Urothelial Bladder Carcinoma (2014, neutral): “Median survival for patients with recurrent or metastatic bladder cancer remains 14–15months with cisplatin-based chemotherapy, and there is no widely recognized second-line therapy 37 .”